Background: Hepatitis A is an infectious viral disease, caused by hepatitis A virus (HAV), endemic in many developing countries. A recent review of the global prevalence of HAV infection and susceptibility by the WHO had few data on the seroprevalence of HAV in Nigeria. This study was designed to determine the seroprevalence of HAV among schoolchildren and adolescents in Kaduna State and to identify factors associated with seropositivity.

Methods: Questionnaires were administered to 403 participants aged 2-19 years, and blood samples were collected during April-July 2009 and screened for anti-HAV IgG using an anti-HAV IgG enzyme immunoassay kit. χ(2) and Fisher's exact tests were used to identify variables associated with the presence of anti-HAV IgG.

Results: The mean ± SD age of the study population was 11.7 ± 3.2 years. Of the 403 serum samples, 29 were positive for HAV, giving an overall seroprevalence of 7.2% (95% CI 4.9-10.2%) among the study population. Seropositivity with respect to age ranged from 4.6% (10/218; 95% CI 2.2-8.3%) in the 11-15 years age group to 30% (3/10; 95% CI 6.7-65.3%) in the ≤5 years age group. Anti-HAV seropositivity was associated with sewage disposal methods and parents' educational level (p < 0.05).

Conclusion: This study shows that the majority of the study population lacked natural immunity (anti-HAV IgG). This low HAV exposure may be attributed to improvements in sanitary conditions and socioeconomic status. Further research involving an older population in different parts of the country is required to determine the current epidemiological pattern of HAV.

Download full-text PDF

Source
http://dx.doi.org/10.1093/trstmh/trt072DOI Listing

Publication Analysis

Top Keywords

anti-hav igg
12
study population
12
hepatitis virus
8
schoolchildren adolescents
8
adolescents kaduna
8
seroprevalence hav
8
years age
8
age group
8
hav
7
study
5

Similar Publications

Background: Hepatitis A infections continue to be a major global public health problem. The epidemiology and seroprevalence of hepatitis A virus (HAV) have important public health implications. This study aimed to retrospectively examine the hepatitis A cases and hepatitis A seroprevalence in our region in our hospital with the highest number of inpatient and outpatient cases in Istanbul.

View Article and Find Full Text PDF
Article Synopsis
  • Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
  • There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
  • There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
View Article and Find Full Text PDF
Article Synopsis
  • The Department of the Air Force conducts antibody testing for hepatitis B and hepatitis A among new recruits at basic training in San Antonio.
  • The results, alongside vaccination records, inform vaccination strategies during training.
  • Analysis from 2023 indicates a significantly higher presence of hepatitis A antibodies compared to hepatitis B antibodies in the trainee population.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates viral hepatitis prevalence among young men who have sex with men (MSM) and transgender women (TGW) in three Brazilian cities, focusing on those aged 15-19.
  • The research collected data through social behavioral questionnaires and blood tests to check for hepatitis A, B, and C antibodies and active infections.
  • Results showed 17.7% had immunity to hepatitis A, while hepatitis B and C prevalence was lower at 2.8% and 0.2%, respectively, indicating a need for improved vaccination and treatment strategies in these populations.
View Article and Find Full Text PDF

Since 2012, universal single-dose HAV vaccination in children aged 3 years and older has been implemented in the Tyva Republic, a region of the Russian Federation. The aim of this prospective non-interventional observational single-center study was to determine the immunological and epidemiological effectiveness of single-dose vaccination against hepatitis A 9 to 11 years after its implementation. The anti-HAV IgG antibodies were determined in two independent cohorts of children who were vaccinated with a single dose of monovalent pediatric inactivated vaccine (HAVRIX 720 EU) in Tyva in 2012 and recruited 9 years (Year 9 Cohort) and 11 years (Year 11 Cohort) after immunization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!